We are live on ! Find out more

Solid Biosciences

SLDB

Market cap $937M

8.74 USD

+0.04

0.46%

At close Updated Sep 14, 4:00 PM EDT

Pre-market

After hours

8.87

+0.13

1.49%

1 day

0.46%

5 days

-12.6%

1 month

-5%

3 months

18.75%

6 months

16.84%

Year to date

60.37%

1 year

59.2%

5 years

-77.15%

10 years

-97.42%

About: Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.

Employees: 121

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 33.3%

Neutral 66.7%

Negative 0%

Solid Biosciences Inc. (SLDB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Solid Biosciences Inc. (SLDB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Solid Biosciences Inc. (SLDB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Solid Biosciences to Participate at Upcoming Investor Conferences

CHARLESTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: 2026 Cantor Global Healthcare Conference Bo Cumbo, President and CEO, and Gabriel Books, M.D.

Solid Biosciences to Participate at Upcoming Investor Conferences

Solid Biosciences: The Bull Case Is No Longer Just Duchenne

Solid Biosciences is transitioning from a speculative Duchenne gene therapy play to a multi-asset rare disease platform with clinical validation momentum. SLDB's $380.7M cash position funds operations into 2028, supporting high-cost Phase 3 SGT-003 trials and multiple pipeline programs without near-term dilution risk. SGT-003's Phase 1/2 data show strong microdystrophin expression and safety, while additional programs in Friedreich's ataxia and CPVT expand addressable markets.

Solid Biosciences: The Bull Case Is No Longer Just Duchenne

Solid Biosciences Inc. (SLDB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Solid Biosciences Inc. (SLDB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Solid Biosciences Inc. (SLDB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 6,580 restricted stock units (“RSUs”) to one newly hired employee.

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Solid Biosciences to Participate at Upcoming Investor Conferences

CHARLESTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: Jefferies Global Healthcare Conference Bo Cumbo, President and CEO, will be presenting on Wednesday, June 3, 2026, at 7:35 a.m.

Solid Biosciences to Participate at Upcoming Investor Conferences

Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates

- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company's Pediatric Investigation Plan from the European Medicines Agency and Orphan drug designation from the European Commission mark important advancements in the program's global development -

Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates

Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy

- Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part of Solid's integrated, multi-trial development program designed to support registration and global regulatory authorizations for SGT-003 -

Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 8,070 restricted stock units (“RSUs”) to one newly hired employee.

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy

- Solid Biosciences delivers its largest scientific program at the 2026 ASGCT Annual Meeting with 5 oral presentations and 11 posters - CHARLESTOWN, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that multiple abstracts have been accepted for presentation at the upcoming 29th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 11-15, 2026, in Boston, MA.

Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy

See News Rankings

Price charts implemented using Lightweight Charts™